Literature DB >> 17410445

Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Vicki M Park1, Barbara C Mason, Julia Krushkal, Rongling Li, Caroline Riely, Jaquelyn Fleckenstein.   

Abstract

In a prospective therapeutic trial, features of the hepatitis C quasispecies were investigated as possible markers of therapeutic response. Individuals chronically infected with hepatitis C genotype 1 received antiviral therapy consisting of alpha-interferon plus ribavirin. The study targeted the most rapidly evolving segment of the viral genome, hypervariable region 1 within the envelope-2 gene. Among individuals failing to clear virus in response to therapy, significant differences were observed between quasispecies of African-American and Caucasian subjects. While distance measures for synonymous substitutions were similar between racial subgroups, measures of distance at the amino acid level (nonsynonymous substitutions) varied significantly. Taken together, the observed patterns of variability corresponded to reduced host selection pressure against hypervariable region 1 in African-American nonresponders. Reduced selection pressure was present at baseline and persisted through treatment and follow-up, suggesting population stratification of host factors that influence selection pressure on hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410445     DOI: 10.1007/s10620-006-9726-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  59 in total

1.  Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.

Authors:  S C Ray; Q Mao; R E Lanford; S Bassett; O Laeyendecker; Y M Wang; D L Thomas
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.

Authors:  Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

Review 5.  Chronic hepatitis C in African Americans and other minority groups.

Authors:  Jaquelyn Fleckenstein
Journal:  Curr Gastroenterol Rep       Date:  2004-02

6.  HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV.

Authors:  Hongxing Qin; Norah J Shire; Erica D Keenan; Susan D Rouster; M Elaine Eyster; James J Goedert; Margaret James Koziel; Kenneth E Sherman
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

7.  Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia.

Authors:  G Tagariello; M Gerotto; P Pontisso; D Belvini; R Salviato; P Radossi; A Alberti
Journal:  Haemophilia       Date:  2004-01       Impact factor: 4.287

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Authors:  Jennifer M Babik; Mark Holodniy
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

Authors:  Stefania Crotta; Annalisa Stilla; Andreas Wack; Annalisa D'Andrea; Sandra Nuti; Ugo D'Oro; Marta Mosca; Franco Filliponi; R Maurizia Brunetto; Ferruccio Bonino; Sergio Abrignani; Nicholas M Valiante
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  1 in total

Review 1.  Ethnic variations in chronic liver diseases.

Authors:  Nyingi Kemmer; Guy W Neff
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.